Dry mouth, medically known as xerostomia, is a common yet often overlooked condition that affects millions of people worldwide. It occurs when the salivary glands fail to produce enough saliva, leading to discomfort, difficulty swallowing, impaired speech, and an increased risk of dental decay and oral infections. The growing prevalence of chronic diseases, medication-induced dry mouth, and an aging global population are driving demand across the dry mouth treatment market, creating significant opportunities for saliva substitute products and advanced oral care therapeutics. According to the Polaris Market Research report, the Xerostomia Therapeutics Market is witnessing steady growth as healthcare providers and manufacturers focus on improving patient outcomes through innovative treatment solutions.

The global xerostomia therapeutics market was valued at USD 2.31 billion in 2025 and is projected to grow from USD 2.40 billion in 2026 to USD 3.32 billion by 2034, registering a CAGR of 4.1% during the forecast period (2026–2034).

Rising Prevalence of Xerostomia

Xerostomia is commonly associated with aging but is also frequently caused by prescription medications, radiation therapy for head and neck cancers, autoimmune disorders such as Sjögren’s syndrome, diabetes, and neurological conditions. As healthcare systems continue to diagnose more chronic diseases, the number of patients experiencing dry mouth symptoms continues to rise.

The condition not only reduces quality of life but also contributes to tooth decay, gum disease, oral infections, and nutritional challenges due to difficulty chewing and swallowing. These complications are increasing the need for effective treatment options across hospitals, dental clinics, and home healthcare settings.

Expansion of the Dry Mouth Treatment Market

The dry mouth treatment market has evolved considerably with the introduction of prescription medications, over-the-counter products, and advanced oral care formulations. Healthcare providers increasingly recommend personalized treatment approaches based on the underlying cause and severity of xerostomia.

Current treatment options include:

• Saliva substitutes
• Salivary stimulants
• Moisturizing oral gels
• Mouth sprays
• Mouth rinses
• Lozenges
• Prescription sialogogues

Manufacturers are developing longer-lasting formulations that provide sustained moisture while improving patient comfort and convenience. The availability of both prescription and OTC products has expanded access to treatment, encouraging earlier intervention and better symptom management.

Growing Demand for Saliva Substitute Products

Among available therapies, saliva substitute products continue to gain widespread popularity. These products are specifically designed to mimic the lubricating properties of natural saliva and provide temporary relief from oral dryness.

Common saliva substitute products include:

• Artificial saliva sprays
• Oral moisturizing gels
• Hydrating mouth rinses
• Oral lubricating solutions
• Moisturizing lozenges

Patients undergoing chemotherapy, radiation therapy, or long-term medication use frequently rely on these products to maintain oral comfort throughout the day.

Continuous improvements in formulation technology have resulted in products that remain effective for longer durations, reducing the need for repeated application. Manufacturers are also introducing flavor-enhanced, alcohol-free, and sugar-free alternatives to improve patient satisfaction.

Oral Care Therapeutics Transforming Patient Management

The increasing focus on preventive dentistry has accelerated innovation in oral care therapeutics. Modern treatment strategies extend beyond symptom relief by protecting oral tissues, reducing bacterial growth, and improving overall oral health.

Advanced oral care therapeutics now include:

• Prescription salivary stimulants
• Fluoride-based preventive therapies
• Antimicrobial oral rinses
• Bioadhesive moisturizing formulations
• Regenerative therapies targeting salivary gland function

Researchers are also investigating regenerative medicine approaches that may restore damaged salivary glands rather than simply treating symptoms. These innovations could significantly improve long-term disease management for patients with chronic xerostomia.

Key Growth Drivers of the Xerostomia Therapeutics Market

Several factors continue to support expansion of the Xerostomia Therapeutics Market:

Growing elderly population: Aging naturally reduces salivary gland function, increasing demand for long-term treatment solutions.

Medication-induced dry mouth: Widespread use of medications for hypertension, depression, allergies, and chronic illnesses has significantly increased xerostomia cases.

Cancer treatment complications: Patients receiving chemotherapy and radiation therapy frequently experience salivary gland damage, creating demand for effective oral care products.

Expansion of OTC availability: Consumers increasingly prefer easily accessible over-the-counter products that provide immediate symptom relief.

Innovation in product formulations: Longer-lasting moisturizers, improved delivery systems, and regenerative research are expanding therapeutic possibilities.

Discover the Complete Report Here:

https://www.polarismarketresearch.com/industry-analysis/xerostomia-therapeutics-market

List of Key Companies                                             

• Acacia Pharma

• Church & Dwight Co., Inc.

• Cogate-Palmolive Company

• Forward Science

• GaxoSmithKline plc

• Hikma Pharmaceuticas PLC

• Lupin Pharmaceuticas, Inc.

• Mission Pharmaca Company

• OraCoat

• Parnel Pharmaceuticals, Inc.

• Pendopharm

• Pfizer Inc.

• Recordati Industria Chimica e Farmaceutica S.p.A

• Sun Pharmaceutica Industries Ltd.

• Synedgen, Inc.

Regional Market Outlook

North America remains the largest regional market due to high healthcare spending, strong awareness of oral health conditions, and broad availability of prescription and OTC xerostomia therapies.

Europe continues to experience stable growth supported by advanced dental care services and increasing diagnosis of chronic diseases.

Asia-Pacific is expected to witness the fastest growth during the forecast period as healthcare infrastructure improves, populations age, and awareness of oral health continues to expand across emerging economies.

Future Opportunities

The future of the Xerostomia Therapeutics Market will be shaped by technological innovation and patient-centered care. Key opportunities include:

• Development of regenerative salivary gland therapies
• AI-assisted oral health monitoring
• Personalized treatment approaches
• Expansion of tele-dentistry services
• Growth in e-commerce distribution of oral care products
• Advanced bioadhesive saliva replacement technologies

Manufacturers investing in innovative formulations and digital healthcare integration are expected to strengthen their competitive position in the coming years.

Conclusion

The expanding dry mouth treatment market, increasing adoption of saliva substitute products, and continuous innovation in oral care therapeutics are transforming the management of xerostomia worldwide. As awareness grows and research delivers more effective treatment options, the Xerostomia Therapeutics Market is expected to maintain steady growth. Advances in prescription therapies, over-the-counter formulations, regenerative medicine, and digital healthcare solutions will continue improving patient outcomes while creating new opportunities for healthcare providers and industry participants.

More Trending Latest Reports By Polaris Market Research:

Monoclonal Antibodies (Mabs) Market

Hemodialysis Market

Sterilization Wrap Market

U.S. Dupixent Market

Hospital Supplies Market

Gamete Preservation Market

Heparin Calcium Market

Male Urinary Incontinence Market